Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate how people who frequently use marijuana respond to a stressful task, and if a medication (oxytocin) affects this response.


Clinical Trial Description

Stress is commonly associated with drug craving and relapse in substance-dependent individuals. Several studies indicate that hypothalamic neuropeptides may mediate behavioral response to stress. For example, preclinical and clinical investigations have indicated that the neuropeptide oxytocin exerts anxiolytic effects in stress paradigms. Several studies have indicated that oxytocin promotes trust, social bonding, and calmness; however, little is known about the potential anxiolytic affects of oxytocin in marijuana-dependent individuals. A preclinical study investigating the effects and mechanism of lithium on cannabinoid withdrawal in rats had positive findings, with increasing oxytocin levels hypothesized to moderate this effect (Cui et al, 2001). Given the anxiolytic nature of oxytocin, it may have a therapeutic role in ameliorating the negative affect commonly observed prior to relapse in marijuana-dependent individuals, as well as the anxiety associated with marijuana withdrawal. This pilot protocol will provide important preliminary data on the effect of oxytocin on stress in marijuana-dependent individuals. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01335789
Study type Interventional
Source Medical University of South Carolina
Contact
Status Completed
Phase N/A
Start date March 2011
Completion date July 2012

See also
  Status Clinical Trial Phase
Active, not recruiting NCT00875836 - Buspirone Treatment for Marijuana Dependence Phase 4
Completed NCT00893269 - The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep Phase 1
Completed NCT00490269 - Ph1 Marinol Interaction Study - Part 2 - 1 Phase 1
Completed NCT02579421 - Hormones and Reduction in Co-users of Marijuana and Nicotine N/A
Terminated NCT01598896 - Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia Phase 2/Phase 3
Completed NCT00373295 - Effect of Baclofen on Marijuana Withdrawal and Relapse Phase 2
Active, not recruiting NCT01827332 - Effect of Oxytocin on Craving and Therapy Response N/A
Terminated NCT00438139 - Ph1 Marinol Interaction Study - Part 1 - 1 Phase 1
Completed NCT02955329 - Vaping THC From Electronic Cigarettes Phase 3
Completed NCT02439814 - Pregnenolone and Marijuana Dependence Phase 2
Completed NCT01039415 - Attempts to Stop/Reduce Marijuana Among Dependent Users N/A
Completed NCT01347762 - Nabilone for Cannabis Dependence: A Pilot Study Phase 2/Phase 3
Completed NCT00270803 - The Effects of Marijuana on Orientation and Motor Coordination and Brain Metabolism in Regular Smokers of Marijuana N/A
Completed NCT01020019 - Combined Pharmacotherapy for Cannabis Dependency Phase 2/Phase 3
Completed NCT02030665 - Marijuana Treatment Project 4 N/A
Completed NCT00107588 - Marijuana Treatment Project - 3 N/A
Completed NCT02011516 - Baclofen Effects on Marijuana Dependence Phase 2
Recruiting NCT00598052 - Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy N/A
Completed NCT00350649 - Maximizing the Efficacy of Cognitive Behavior Therapy and Contingency Management Phase 2
Completed NCT00374127 - Comparison Between Marijuana Smoked in Cigarette Paper Versus Cigar Paper Phase 2